Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.